Trial · NCT01434602
Participant flow30
How many started, completed or left each group, period by period.
1 to 20 of 30
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase I Dose Escalation | STARTED | Phase I Dose Level I Sorafenib 400mg Twice Daily + Everolimus 5mg Daily | 6 | |
| Phase I Dose Escalation | STARTED | Phase I Dose Level -1 Sorafenib 400mg Twice Daily, 7 Days on, 7 Off + Everolimus 5mg Daily | 7 | |
| Phase I Dose Escalation | STARTED | Phase 2 Group A Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase I Dose Escalation | STARTED | Phase 2 Group B Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase I Dose Escalation | STARTED | Phase 2 Group C Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase I Dose Escalation | COMPLETED | Phase I Dose Level I Sorafenib 400mg Twice Daily + Everolimus 5mg Daily | 6 | |
| Phase I Dose Escalation | COMPLETED | Phase I Dose Level -1 Sorafenib 400mg Twice Daily, 7 Days on, 7 Off + Everolimus 5mg Daily | 6 | |
| Phase I Dose Escalation | COMPLETED | Phase 2 Group A Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase I Dose Escalation | COMPLETED | Phase 2 Group B Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase I Dose Escalation | COMPLETED | Phase 2 Group C Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase I Dose Escalation | NOT COMPLETED | Phase I Dose Level I Sorafenib 400mg Twice Daily + Everolimus 5mg Daily | 0 | |
| Phase I Dose Escalation | NOT COMPLETED | Phase I Dose Level -1 Sorafenib 400mg Twice Daily, 7 Days on, 7 Off + Everolimus 5mg Daily | 1 | |
| Phase I Dose Escalation | NOT COMPLETED | Phase 2 Group A Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase I Dose Escalation | NOT COMPLETED | Phase 2 Group B Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase I Dose Escalation | NOT COMPLETED | Phase 2 Group C Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase II Recommended Phase 2 Dose | STARTED | Phase I Dose Level I Sorafenib 400mg Twice Daily + Everolimus 5mg Daily | 0 | |
| Phase II Recommended Phase 2 Dose | STARTED | Phase I Dose Level -1 Sorafenib 400mg Twice Daily, 7 Days on, 7 Off + Everolimus 5mg Daily | 0 | |
| Phase II Recommended Phase 2 Dose | STARTED | Phase 2 Group A Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 12 | |
| Phase II Recommended Phase 2 Dose | STARTED | Phase 2 Group B Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 40 | |
| Phase II Recommended Phase 2 Dose | STARTED | Phase 2 Group C Dose Level -1 Sorafenib 400mg Twice Daily 7 Days on, 7 Off + Everolimus 5mg Daily | 21 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01434602/flow